EndoGastric Solutions, Ritter Pharmaceuticals & more — 8 GI company key notes

Here are eight updates on GI companies from the past week:

Advertisement

Zealand Pharma and UniQuest, the commercialization company of The University of Queensland in Australia, are collaborating to develop new drug candidates inspired by venoms to treat gastrointestinal diseases.

William Chey, MD, is joining Ritter Pharmaceuticals’ medical advisory board.

Smart Medical Systems closed an $8 million series B financing round, which will primarily be used to commercialize its G-Eye system.

Exact Sciences CEO Kevin Conroy sold 101,488 shares of stock for approximately $4.64 million Feb. 9.

Takeda Pharmaceutical became one of 13 companies and one of two pharmaceutical companies to receive global Top Employer status for 2018.

EndoGastric Solutions published five-year follow-up data on the effectiveness of transoral incisionless fundoplication 2.0 procedures in controlling gastroesophageal reflux disease symptoms.

University of Alabama at Birmingham Medicine partnered with patient engagement and care management platform SeamlessMD.

More articles on gastroenterology: 
5 key observations on NJ ASC landscape post-‘One-Room Bill”
To prevent the spread of norovirus at the Olympics, athletes told to fist-bump, not shake hands: 4 things to know
Partner at Seaside Surgery Center receives board certification — 4 things to know

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.